Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Lance Okeke

HIV/AIDS Medicine · Duke University

View

Dr. Raphael J. Landovitz

HIV/AIDS Medicine · UCLA

View

Dr. Aniruddha Hazra

HIV/AIDS Medicine · UCMC

View

Dr. Shital Patel

HIV/AIDS Medicine · BCM

View

Dr. Monica Gandhi

HIV/AIDS Medicine · UCSF

View

Dr. Ashwin Balagopal

HIV/AIDS Medicine · Johns Hopkins

View

Dr. Ofole Mgbako

HIV/AIDS Medicine · NYU Langone

View

Dr. Joshua Barocas

HIV/AIDS Medicine · CU Anschutz Medical Campus

View

Dr. Chris Beyrer

Global Health · Duke University

View

Dr. Keith Kaye

General ID · RU

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Incidence of AIDS-Defining Conditions Among Adults With Perinatally Acquired HIV After Transition to Adult HIV Care in the United States and Canada, 2000-2022.

    Dec 24, 2025DOI: 10.1093/cid/ciaf300Journal ArticleCID

    Written by: Nel Jason L HawCatherine R LeskoDerek K NgJennifer O LamKelly GeboTimothy R SterlingCharles S RabkinJun LiKate BuchaczAllison AgwuKeri AlthoffNorth American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)

    Find these authors on Roon

    KG
    Dr. Kelly Gebo
    HIV/AIDS Medicine · GW

    Summary

    BACKGROUND: Little is known about the incidence of AIDS-defining conditions (ADCs) among people with perinatally acquired human immunodeficiency virus (PHIV) who transitioned to adult human immunodeficiency virus (HIV) care in the United States and Canada. We described the incidence among PHIV and compared it with that among those with non-perinatally acquired HIV (non-PHIV) and across calendar era.METHODS: Using data from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) from 2000-2022, we estimated weighted mean cumulative counts (MCCs) of ADCs, comparing people with PHIV and non-PHIV acquisition risk groups aged 18-40 years engaged in adult HIV care. The weights accounted for differences in characteristics among HIV acquisition risk groups as well as informative censoring. We calculated 95% confidence intervals using bootstrapping. We stratified results before and after 2012, when the immediate start of antiretroviral therapy was first recommended.RESULTS: There were 5429 ADCs among 22 950 people with HIV. Among those with PHIV, the MCC of ADCs by 3 years in adult HIV care was 26 per 100 persons (95% confidence interval, 15-40) in 2000-2011 and 16 per 100 (5-21) in 2012-2022. Within each calendar era, weighted MCCs of ADCs among people with PHIV were similar or lower than in non-PHIV groups. Within each HIV acquisition risk group, weighted MCCs of ADCs were lower in 2000-2011 than in 2012-2022.CONCLUSIONS: People with PHIV who transitioned to adult HIV care did not experience a greater ADC incidence than those with non-PHIV. This emphasizes the importance of continued engagement in adult HIV care, as it provides critical opportunities for ADC prevention and management.
    KGDr. Kelly Gebo

    Dr. Kelly Gebo

    Infectious Disease · HIV & AIDS Medicine
    George Washington University
    kellyg